Montvale, NJNCT07725497Now EnrollingIRB Ready

Anemia Clinical Trial in Montvale, NJ

Access cutting-edge anemia treatment through this phase 2 clinical trial at a research site in Montvale. Study-provided care at no cost to qualified participants.

Sponsored by Memorial Sloan Kettering Cancer Center

Quick Self-Assessment

See if you qualify for this Montvale location

Preparing your pre-screening questions…

Expert Care in Montvale

Access anemia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related anemia treatment provided free

Apply for This Montvale Location

Check if you qualify for this anemia clinical trial in Montvale, NJ

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Montvale

    Convenient for NJ residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Montvale site if eligible
  4. 4Begin participation

About This Anemia Study in Montvale

The researchers are doing this study to test whether luspatercept works to improve hemoglobin levels in people with anemia caused by chronic kidney disease (CKD). The researchers will also test whether luspatercept is a safe treatment that causes few or mild side effects in participants.

Sponsor: Memorial Sloan Kettering Cancer Center

Who Can Participate

Inclusion Criteria

Documentation of Anemia due to CKD
Patients must have a Hb ≤ 9.5 g/dL on two separate occasions within 4 weeks prior to enrollment.
Do not anticipate red cell transfusion within the following 4 weeks and no history of red cell transfusion in three weeks prior to enrollment.
Ferritin ≥100 ng/mL and iron transferrin saturation (TSAT) ≥ 20%.
Serum folate \> 4 ng/mL
Serum vitamin B12 \> 250 pg/mL
Patients may have received iron, B12 and folic acid repletion if initiated \> 6 weeks prior to enrollment. Patients who are already on iron, B12 and folic acid repletion can continue throughout the trial.
TSH, T4 within institutional normal limits. Documentation of Chronic Kidney Disease
Chronic kidney disease defined as a GFR between 30-60 mL/min/1.73m2 for ≥ 3 months calculated by the 2021 CKD-EPI creatinine equation for eGFR, the 2021 CKD-EPI creatinine-cystatin C equation, or creatinine clearance measured by a 24-hour urine collection. Prior Treatment with Erythrocyte Stimulating Agents (ESA)
Eligible patients will not have had recent (within past 3 weeks) erythrocyte stimulating agents (ESA) prior to enrollment unless they are hyporesponsive to ESA therapy.
Patients are eligible if they are either hyporesponsive to ESA therapy or unwilling to accept ESAs. defined by the Kidney Disease Outcomes Quality Initiative (KDOQI) as the inability to achieve/maintain a desired hemoglobin (herein defined as a hemoglobin of \> 9.0 g/dL) using a maximum dose of erythropoietin (450 units/kg/week IV or 300 units/kg/week SQ or the darbepoetin equivalent using the conversion of 45,000 units/week of epoetin = 100 mcg/week of darbepoetin).
ECOG Performance Status of ≤ 2
Not Pregnant and Not Nursing Required Organ Function
Adequate hematologic function defined as follows:
Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3
Platelets ≥ 75,000 cells/mm3
Adequate hepatic function defined as follows:
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) (patients with known Gilbert's disease who have bilirubin level ≤ 3 x ULN may be enrolled)
AST and ALT ≤3 x institutional ULN
Comorbid Conditions
Patients with a history of a solid organ malignancy can be included if they have been in remission for at least 12 months.

Exclusion Criteria

Evidence of recent (within previous 4 weeks) bleeding including gastrointestinal to explain anemia.
Evidence of hemolysis (LDH ≥ 2 x ULN and haptoglobin below lower limit of normal)
Known diagnosis of myelodysplastic syndrome or any known hematologic malignancy \[not including monoclonal of undetermined significance (MGUS) or monoclonal b-cell lymphocytosis (MBL)\] not in remission
GFR \< 30 mL/min/1.73m2 or on dialysis (no available data for luspatercept on HD)
Acute kidney injury ( ≤ 3 months)
Uncontrolled hypertension: repeated elevations of SBP ≥ 150 mmHg and/or DBP ≥ 100 mmHg despite adequate treatment
Known hemoglobinopathy.
Known inherited or acquired thrombophilia.
History of venous thromboembolism within past 2 years
Cerebral vascular accident within past 2 years
Recent (within 2 years) myocardial infarction
Allergy to luspatercept components

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Montvale?

Yes, this clinical trial (NCT07725497) has an active research site in Montvale, NJ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Anemia Treatment Options in Montvale, NJ

If you're searching for anemia treatment options in Montvale, NJ, this clinical trial (NCT07725497) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Montvale research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced anemia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all anemia clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Montvale, NJ

See all heart attack clinical trials recruiting in Montvale — not just this study.

Browse Heart Attack Trials in Montvale →

Browse More Trials by Condition

Heart Attack TrialsAnemia TrialsSickle Cell Disease TrialsThalassemia TrialsParoxysmal Nocturnal Hemoglobinuria TrialsMyocardial Infarction TrialsIron Deficiency Anemia TrialsFanconi Anemia TrialsAll Conditions →

Ready to Join in Montvale?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Montvale, NJ